Wockhardt has launched three new products viz., Levofloxacin tablets,  Donepezil tablets and Venlafaxine extended-release capsules in the United States during last three weeks. The company has received final approval from US FDA for marketing the 250mg, 500mg and 750mg tablets of Levofloxacin, which is used for treating a broad spectrum of bacterial infections. Levofloxacin is a generic version of Levaquin, marketed in the United States by Ortho McNeil (Johnson & Johnson). Wockhardt launched the product on the same day.

Habil Khorakiwala, chairman, said, “After Donepezil tablets on May 31st and Venlafaxine extended-release capsules on June 1st, this is our third new product launch in the United States, within the past twenty-one days. Each of these products was launched on the date the generic market opportunity opened. While business on the existing products has been growing, it is the steady infusion of new products that has enabled us to put our US business on a path of rapid growth.”.

Donepezil, a generic version of Eisai’s brand Aricept, is amongst the most widely used drugs in treating Alzheimer’s disease, incidences of which are rapidly increasing the world over due to a steady increase in aging population.

Venlafaxine extended release capsule, a generic version of Pfizer’s Effexor XR, is one the most widely used antidepressant drugs. The product is a capsule containing specially designed pellets to extend their release over 24 hours and requires specialised technology and manufacturing capability.